NVS R&D Expenses

Novartis AG Common Stock · R&D Expenses

NVS logo

NVS R&D Expenses

Latest reported$11.28B
NVS TTM R&D Expenses ($573.00M → $11.28B)
High-resolution chart · PNG

NVS r&d expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Novartis AG Common Stock R&D Expenses — Trailing twelve months (TTM) (USD)
Period endingR&D Expenses (USD)
11,279,674,000
11,247,784,000
10,873,784,000
10,879,000,000
10,327,000,000
9,967,000,000
10,022,000,000
9,747,000,000
11,280,000,000
11,217,000,000
11,371,000,000
11,246,000,000
9,863,000,000
10,057,000,000
9,802,000,000
9,769,000,000
9,607,000,000
9,509,000,000
9,540,000,000
9,464,000,000
9,230,000,000
9,271,000,000
8,980,000,000
9,500,000,000
9,553,000,000
9,163,000,000
9,402,000,000
8,948,000,000
8,896,000,000
8,971,000,000
8,654,000,000
8,757,000,000
8,849,000,000
8,785,000,000
8,972,000,000
9,054,000,000
9,039,000,000
9,167,000,000
9,039,000,000
8,927,000,000
8,893,000,000
8,909,000,000
8,935,000,000
9,000,000,000
8,971,000,000
8,943,000,000
9,086,000,000
9,246,000,000
9,301,000,000
9,370,000,000
9,457,000,000
9,381,000,000
9,356,000,000
9,394,000,000
9,332,000,000
9,234,000,000
9,518,000,000
9,630,000,000
9,583,000,000
9,652,000,000
9,725,000,000
9,221,000,000
9,070,000,000
8,626,000,000
7,903,000,000
7,812,000,000
7,469,000,000
7,155,000,000
7,272,000,000
7,237,000,000
7,217,000,000
7,230,000,000
6,840,000,000
6,602,000,000
6,430,000,000
6,121,000,000
5,973,000,000
5,697,000,000
5,326,000,000
5,260,000,000
5,047,000,000
4,890,000,000
4,846,000,000
4,608,000,000
4,479,000,000
4,347,000,000
4,207,000,000
4,065,000,000
3,881,000,000
3,860,000,000
3,756,000,000
3,758,000,000
3,556,000,000
3,328,000,000
2,485,000,000
1,391,000,000
715,000,000
560,000,000
560,000,000
560,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.